• Edwards Lifesciences Corporation Acquires CardiAQ Valve Technologies

    August 26, 2015

    Aug. 26, 2015, Irvine, CA — Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that it has closed its acquisition of CardiAQ Valve Technologies, Inc., a privately held company and developer of a transcatheter mitral valve replacement system. Edwards announced last month that it had signed an agreement to acquire CardiAQ.   Press Release

    Read More
  • Remedy Pharmaceuticals Publication

    July 28, 2015

    July 28, 2015, New York — Remedy Pharmaceuticals, a company focused on the development and commercialization of CIRARA, a breakthrough drug treating acute central nervous system conditions such as stroke, today announced publication of a peer-reviewed paper that confirms administering CIRARA for pharmacological targeting of the Sur1-Trpm4 channel in human ischemic stroke to reduce blood-brain barrier disruption and cerebral edema is a promising therapeutic strategy. Press Release

    Read More
  • 480 Biomedical, Inc. Receives $1.2M from Broadview

    June 18, 2015

    June 18, 2015, Watertown, MA — 480 Biomedical, Inc., a clinical stage company developing novel bioresorbable scaffold products for the vasculature, announced today $1.2 million in funding from Broadview Ventures. The financing is a second close on a previously announced $10.5 million in Series C funding round from existing investors. The Broadview funds will support the development of a bioresorbable scaffold to treat children with pulmonary artery stenosis (PAS), a narrowing in the branches of the pulmonary artery that reduces blood flow to the lungs and can lead to heart failure. Press R

    Read More
  • Pulmokine Receives $1M from Broadview

    March 3, 2015

    March 3, 2015 Pulmokine announced today that it has entered into an agreement with Broadview Ventures for $1 Million. Proceeds will be used to advance Pulmokine’s lead candidate, PK10571, into Phase 1 clinical trials in patients with pulmonary arterial hypertension (PAH). Press Release

    Read More